Logo for Sol-Gel Technologies Ltd

Sol-Gel Investor Relations Material

Latest events

Logo for Sol-Gel Technologies Ltd

M&A Announcement

Sol-Gel
Logo for Sol-Gel

Q3 2024

15 Nov, 2024
Logo for Sol-Gel

Q2 2024

17 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Sol-Gel Technologies Ltd

Access all reports
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. The company offers Phase 5 (clobex), a prescription liquid medication designed to selectively target specific classes of dendritic cells that initiate the immune response. Its smevetch is a topical compounded drug that contains tacrolimus and dexamethasone. The company was formerly known as Silex Platform Limited and changed its name to Sol-Gel Technologies Ltd. in June 2010. Sol-Gel Technologies Ltd. is based in London, the United Kingdom.